Dyax Corp. DYAX today announced positive results from both
preclinical studies of the investigational product DX-2930 and its
biomarker assay program for detection of contact system activation of
plasma kallikrein (pKal). Data were presented at the 55th
American Society of Hematology (ASH) Annual Meeting and Exposition
taking place December 7-10 in New Orleans, LA.#ASH13
DX-2930 is Dyax's fully human monoclonal antibody inhibitor of pKal.
Dyax is developing DX-2930 to be a long-acting prophylactic agent that
prevents hereditary angioedema (HAE) attacks. Development plans include
a dosage formulation that will permit infrequent self-administration by
small volume, subcutaneous injection. DX-2930 is currently being studied
in a placebo-controlled, dose-escalation Phase 1 trial in healthy
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in